surpass 6 tirzepatide New SURPASS-CVOT Ad Hoc Analysis: outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r/Zepbound PDF] Early-Onset Type 2 Diabetes
Pay in 4 interest-free payments of $6.72 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
![surpass 6 tirzepatide New SURPASS-CVOT Ad Hoc Analysis: outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r/Zepbound PDF] Early-Onset Type 2 Diabetes](https://figures.semanticscholar.org/47f2cbae01360a57626762aec4a9f115ff7b6417/6-Figure1-1.png)
![surpass 6 tirzepatide New SURPASS-CVOT Ad Hoc Analysis: outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r/Zepbound PDF] Early-Onset Type 2 Diabetes](https://dom-pubs.onlinelibrary.wiley.com/cms/asset/47860007-09fe-465b-b601-b6468c9d3780/dom16337-fig-0004-m.jpg)
![surpass 6 tirzepatide New SURPASS-CVOT Ad Hoc Analysis: outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r/Zepbound PDF] Early-Onset Type 2 Diabetes](https://mumcdnstorage.blob.core.windows.net/dwnews/2026/05/iStock-2211882789.jpg)
![surpass 6 tirzepatide New SURPASS-CVOT Ad Hoc Analysis: outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r/Zepbound PDF] Early-Onset Type 2 Diabetes](https://mms.businesswire.com/media/20231003113775/en/1905467/22/EASD_2023_Image.jpg)





















